Leukemia

An expert discusses new treatment options for patients diagnosed with CLL.

Patients with relapsed or refractory chronic lymphocytic leukemia may have more options now than ever before, according to William G. Wierda, M.D., Ph.D.

While novel agents continue to evolve in the treatment landscape for chronic lymphocytic leukemia, many may start to be combined in the front-line setting as well, according to Matthew S. Davids, M.D., MMSc.

Here are the top 5 CURE stories for March 2019.

Helping others is the last phase of recovery.

Time-limited treatment could be the new wave of research in the treatment of chronic lymphocytic leukemia (CLL), according to Nicole Lamanna, M.D.

Here are the top 5 CURE stories for February 2019.

Brian Boyle, who plays center for the New Jersey Devils, has announced that his blood cancer is in remission.

The Food and Drug Administration granted a priority review to Tibsovo (ivosidenib) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.

A CLL diagnosis comes with new challenges, from understanding signs and symptoms and what the different stages mean.

Understanding CLL as a chronic disease.

Knowing treatment options and the possibilities of supportive care.

Utilizing clinical trials and understanding potential side effects and complications.

Finding follow-up care and emotional support.

Serving as a caregiver for a loved one going through a CLL diagnosis and treatment while utilizing resources to take care of oneself.

A list of helpful resources to assist people with CLL and their families cope with the emotional and practical aspects of the disease.

Imbruvica (ibrutinib) may be superior to standard of care in elderly patients with untreated chronic lymphocytic leukemia (CLL), according to phase 3 findings published in the New England Journal of Medicine.

Ian W. Flinn, M.D., Ph.D., discusses the use of Copiktra, which was approved in September for patients with relapsed/refractory chronic lymphocytic leukemia.

The Food and Drug Administration approved Imbruvica plus Gazyva for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

An acute promyelocytic leukemia survivor reflects on fear, courage and the future.

Toronto’s Jeff Lipton, PhD, MD, FRCPC, shares his thoughts on the outlook for blood cancers.

In an interview with CURE, Filippo Milano, M.D., Ph.D., explains what cord blood transplantation is and why it is important for patients to learn more.

Brian Koffman is a family physician who used his own CLL diagnosis to start a group that informs other patients and their loved ones.

The Food and Drug Administration (FDA) approved Sprycel (dasatinib) plus chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia